David R. McAvoy
General Counsel chez TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Fortune : 14 816 $ au 31/03/2024
Profil
David R.
McAvoy is currently the Director at Villages of Indiana and the Chief Legal Officer & Executive Vice President at Teva Pharmaceutical Industries Ltd.
He previously worked as the General Counsel-Lilly Emerging Markets at Eli Lilly & Co., Chief Compliance Officer & General Counsel at Vical, Inc., Chief Compliance Officer & General Counsel at Brickell Subsidiary, Inc., Chief Compliance Officer & General Counsel at Endocyte, Inc., and Chief Compliance Officer & General Counsel at Fresh Tracks Therapeutics, Inc. Mr. McAvoy completed his undergraduate degree at the University of Notre Dame and his graduate degree at Indiana University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 02/10/2023 | 16 371 ( 0,27% ) | 14 816 $ | 31/03/2024 |
Postes actifs de David R. McAvoy
| Sociétés | Poste | Début |
|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | General Counsel | 01/03/2024 |
| Villages of Indiana | Director/Board Member | - |
Anciens postes connus de David R. McAvoy
| Sociétés | Poste | Fin |
|---|---|---|
| FRESH TRACKS THERAPEUTICS, INC. | Compliance Officer | 01/09/2023 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Compliance Officer | - |
Brickell Subsidiary, Inc.
 Brickell Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology Brickell Subsidiary, Inc. operates as a clinical-stage pharmaceutical company. It focuses on the development of differentiated, innovative drug therapies for the treatment of skin diseases. The firm specializes in Hyperhidrosis, Cutaneous T-Cell Lymphoma and Psoriasis areas. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in November 2009 and is headquartered in Boulder, CO. | Compliance Officer | - |
| ENDOCYTE, INC. | Compliance Officer | - |
Formation de David R. McAvoy
| University of Notre Dame | Undergraduate Degree |
| Indiana University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
| FRESH TRACKS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
Brickell Subsidiary, Inc.
Brickell Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology Brickell Subsidiary, Inc. operates as a clinical-stage pharmaceutical company. It focuses on the development of differentiated, innovative drug therapies for the treatment of skin diseases. The firm specializes in Hyperhidrosis, Cutaneous T-Cell Lymphoma and Psoriasis areas. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in November 2009 and is headquartered in Boulder, CO. | Health Technology |
Endocyte, Inc.
 Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
| Villages of Indiana |
